Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Understanding the Role of Orexin Neuropeptides in Drug Addiction: Preclinical Studies and Translational Value
Alessandra Matzeu, Rémi Martin‐Fardon
Frontiers in Behavioral Neuroscience (2022) Vol. 15
Open Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

The Orexin/Hypocretin System, the Peptidergic Regulator of Vigilance, Orchestrates Adaptation to Stress
Miklós Jászberényi, Balázs Thurzó, Zsolt Bagosi, et al.
Biomedicines (2024) Vol. 12, Iss. 2, pp. 448-448
Open Access | Times Cited: 22
The orexin story and orexin receptor antagonists for the treatment of insomnia
Clemens Muehlan, Catherine Roch, Cédric Vaillant, et al.
Journal of Sleep Research (2023) Vol. 32, Iss. 6
Open Access | Times Cited: 39
Structural and functional organization of the midline and intralaminar nuclei of the thalamus
Robert P. Vertes, Stephanie B. Linley, Amanda K. P. Rojas
Frontiers in Behavioral Neuroscience (2022) Vol. 16
Open Access | Times Cited: 38
Discovery and first-time disclosure of CVN766, an exquisitely selective orexin 1 receptor antagonist
Angela Glen, Roland W. Bürli, David G. Livermore, et al.
Bioorganic & Medicinal Chemistry Letters (2024) Vol. 100, pp. 129629-129629
Open Access | Times Cited: 8
Targeting the orexin/hypocretin system for the treatment of neuropsychiatric and neurodegenerative diseases: From animal to clinical studies
Marc Ten-Blanco, África Flores, Luigia Cristino, et al.
Frontiers in Neuroendocrinology (2023) Vol. 69, pp. 101066-101066
Open Access | Times Cited: 19
Sleep loss and addiction
Luis Angel López-Muciño, Fabio Garcı́a-Garcı́a, Jonathan Cueto‐Escobedo, et al.
Neuroscience & Biobehavioral Reviews (2022) Vol. 141, pp. 104832-104832
Closed Access | Times Cited: 26
Effects of daridorexant on rest/wake activity patterns and drinking in adult rats exposed to chronic ethanol vapor in adolescence
Leslie R. Amodeo, Derek N. Wills, Jason Benedict, et al.
Alcohol (2025)
Open Access
The Neuroscience of Addiction
Ranjit Singha
Advances in medical education, research, and ethics (AMERE) book series (2025), pp. 257-288
Closed Access
A Preliminary Report on the Effects of Daridorexant in Patients with Comorbid Insomnia and Substance Use Disorders
Marco Di Nicola, Maria Pepe, Lorenzo Bonomo, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 3, pp. 378-378
Open Access
Alternative use of suvorexant (Belsomra®) for the prevention of alcohol drinking and seeking in rats with a history of alcohol dependence
Francisco J. Flores‐Ramirez, Jessica M. Illenberger, Glenn Pascasio, et al.
Frontiers in Behavioral Neuroscience (2022) Vol. 16
Open Access | Times Cited: 16
Neurotensin and Alcohol Use Disorders: Towards a Pharmacological Treatment
Francisco D. Rodríguez, Manuel Lisardo Sánchez, Rafael Coveñas
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 10, pp. 8656-8656
Open Access | Times Cited: 9
Orexin-mediated Motivated Arousal and Reward Seeking.
Theresa E. Bjorness, Robert Greene
Peptides (2024) Vol. 180, pp. 171280-171280
Closed Access | Times Cited: 3
Neurobiology of Stress-Induced Nicotine Relapse
Xinyu Wang, Yun Chen, Jing Dong, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 3, pp. 1482-1482
Open Access | Times Cited: 2
Sex-dimorphic functions of orexin in neuropsychiatric disorders
Jinghan Zhang, Kangyu Jin, Bing Chen, et al.
Heliyon (2024) Vol. 10, Iss. 16, pp. e36402-e36402
Open Access | Times Cited: 2
Effects of light therapy on sleep/wakefulness, daily rhythms, and the central orexin system in a diurnal rodent model of seasonal affective disorder
Allison Costello, Katrina Linning‐Duffy, Carleigh Vandenbrook, et al.
Journal of Affective Disorders (2023) Vol. 332, pp. 299-308
Open Access | Times Cited: 6
Neuronal biomarkers as potential therapeutic targets for drug addiction related to sex differences in the brain: Opportunities for personalized treatment approaches
Maryam Sardari, Farina Mohammadpourmir, Oveis Hosseinzadeh Sahafi, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2024) Vol. 134, pp. 111068-111068
Closed Access | Times Cited: 1
The Neurocircuitry of Substance Use Disorder, Treatment, and Change: A Resource for Clinical Psychiatrists
Caesar G. Imperio, Frances R. Levin, Diana Martínez
American Journal of Psychiatry (2024) Vol. 181, Iss. 11, pp. 958-972
Closed Access | Times Cited: 1
Healthy Sleep, Orexin System and Addiction
Ana Clementina Equihua-Benítez, Fabio Garcı́a-Garcı́a
Revista Internacional de Investigación en Adicciones (2024) Vol. 10, Iss. 1, pp. 80-90
Closed Access | Times Cited: 1
Contribution of Visceral Systems to the Development of Substance Use Disorders: Translational Aspects of Interaction between Central and Peripheral Mechanisms
Д. И. Перегуд, N. V. Gulyaeva
Biochemistry (Moscow) (2024) Vol. 89, Iss. 11, pp. 1868-1888
Open Access | Times Cited: 1
Neural correlates and potential targets for the contribution of orexin to addiction in cortical and subcortical areas
Masoumeh Kourosh‐Arami, Masoumeh Gholami, Seyed Sajjad Alavi-Kakhki, et al.
Neuropeptides (2022) Vol. 95, pp. 102259-102259
Closed Access | Times Cited: 6
Subregional Differences in Alcohol Modulation of Central Amygdala Neurocircuitry
Mariam Melkumyan, Yuval Silberman
Frontiers in Molecular Neuroscience (2022) Vol. 15
Open Access | Times Cited: 5
Leptin, ghrelin, nesfatin-1, and orexin-A plasma levels in girls with premature thelarche
Negin ALMASİ, Hümeyra Zengin, Nermin Koç, et al.
Journal of Endocrinological Investigation (2022) Vol. 45, Iss. 11, pp. 2097-2103
Closed Access | Times Cited: 3
A novel, non-opioid, selective orexin-1 receptor antagonist for the treatment of substance use disorders
Clare Murray, Jennifer Fox, Christian Heidbreder, et al.
Neuroscience Applied (2024) Vol. 3, pp. 104053-104053
Open Access
Sex-Specific Roles of Hypocretin Receptor Signaling in CRF Neurons on Alcohol Drinking, Anxiety, and BNST Neuronal Excitability
Yihe Ma, Haniyyah Sardar, Max E. Benabou, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Closed Access
Improving Sleep to Address Co-Occurring Substance Use Disorder and Chronic Pain: Exploring the Potential of the Orexin (Hypocretin) System as a Clinical Target
Chung Jung Mun, Matthew J. Reid, Sarah Sarandos, et al.
Current Addiction Reports (2024)
Closed Access
Page 1 - Next Page

Scroll to top